We are live on ! Find out more

Foghorn Therapeutics

FHTX

Market cap $369M

6.22 USD

-0.47

7.03%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

6.34

+0.12

1.93%

1 day

-7.03%

5 days

-12.39%

1 month

19.62%

3 months

45.67%

6 months

9.51%

Year to date

19.85%

1 year

14.97%

5 years

-48.64%

10 years

-65.67%

About: Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Employees: 106

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 55.6%

Negative 0%

Zacks Investment Research

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Zacks Investment Research

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Zacks Investment Research

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.28 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million ; cash runway into the first half of 2028 WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the second quarter ended June 30, 2026.

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Zacks Investment Research

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatistat, as a treatment for essential thrombocythaemia, lymphoma and solid tumours.

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

See News Rankings

Price charts implemented using Lightweight Charts™